BR112014025830A2 - - Google Patents

Info

Publication number
BR112014025830A2
BR112014025830A2 BR112014025830A BR112014025830A BR112014025830A2 BR 112014025830 A2 BR112014025830 A2 BR 112014025830A2 BR 112014025830 A BR112014025830 A BR 112014025830A BR 112014025830 A BR112014025830 A BR 112014025830A BR 112014025830 A2 BR112014025830 A2 BR 112014025830A2
Authority
BR
Brazil
Application number
BR112014025830A
Other languages
Portuguese (pt)
Other versions
BR112014025830A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112014025830A2 publication Critical patent/BR112014025830A2/pt
Publication of BR112014025830A8 publication Critical patent/BR112014025830A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112014025830A 2012-04-20 2013-04-18 Polipeptídeos de ligação ao cd3 BR112014025830A8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261636557P 2012-04-20 2012-04-20
US201261718635P 2012-10-25 2012-10-25
US201361799849P 2013-03-15 2013-03-15
PCT/US2013/037135 WO2013158856A2 (en) 2012-04-20 2013-04-18 Cd3 binding polypeptides

Publications (2)

Publication Number Publication Date
BR112014025830A2 true BR112014025830A2 (enExample) 2017-06-20
BR112014025830A8 BR112014025830A8 (pt) 2017-10-10

Family

ID=49384230

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014025830A BR112014025830A8 (pt) 2012-04-20 2013-04-18 Polipeptídeos de ligação ao cd3

Country Status (16)

Country Link
US (1) US10202452B2 (enExample)
EP (1) EP2839019A4 (enExample)
JP (2) JP6509724B2 (enExample)
KR (1) KR20150004856A (enExample)
CN (1) CN104487587A (enExample)
AU (2) AU2013249267A1 (enExample)
BR (1) BR112014025830A8 (enExample)
CA (1) CA2870545A1 (enExample)
HK (2) HK1207398A1 (enExample)
IL (1) IL235093B (enExample)
IN (1) IN2014MN02293A (enExample)
MX (1) MX366813B (enExample)
RU (1) RU2673153C2 (enExample)
SG (2) SG11201406346SA (enExample)
UA (1) UA119227C2 (enExample)
WO (1) WO2013158856A2 (enExample)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP4279513A3 (en) 2010-11-30 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
EP2699596A4 (en) 2011-04-22 2015-01-14 Emergent Product Dev Seattle PROSTATE-SPECIFIC MEMBRANE-BINDING PROTEINS AND COMPOSITIONS AND METHOD THEREFOR
CA2870545A1 (en) 2012-04-20 2013-10-24 Emergent Product Development Seattle, Llc Cd3 binding polypeptides
AU2014325063B2 (en) 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US9982038B2 (en) 2014-01-24 2018-05-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Antibodies against F glycoprotein of Hendra and Nipah viruses
SG11201609707WA (en) 2014-07-01 2017-01-27 Pfizer Bispecific heterodimeric diabodies and uses thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CA2974453A1 (en) 2015-01-23 2016-07-28 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
AU2016248946C1 (en) 2015-04-13 2024-10-17 Pfizer Inc. Therapeutic antibodies and their uses
RU2706582C2 (ru) 2015-04-13 2019-11-19 Пфайзер Инк. Химерные антигенные рецепторы, нацеленные на антиген созревания B-клеток
RU2754661C2 (ru) * 2015-05-01 2021-09-06 Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния Гликанзависимые иммунотерапевтические молекулы
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN107849148B (zh) 2015-05-21 2023-09-19 哈普恩治疗公司 三特异性结合蛋白质及使用方法
CN104892765B (zh) * 2015-06-29 2018-04-10 深圳市国创纳米抗体技术有限公司 一种抗CD3抗原和Her‑2抗原的双特异性抗体
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
BR112018005573A2 (pt) * 2015-09-21 2019-01-22 Aptevo Research And Development Llc ?polipeptídeos de ligação a cd3?
WO2017055391A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
KR102850929B1 (ko) 2015-12-09 2025-08-27 에프. 호프만-라 로슈 아게 항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US11339225B2 (en) 2016-05-12 2022-05-24 Asclepius (Suzhou) Technology Company Group, Co., Ltd. Bispecific antigen-binding construct and preparation method and use thereof
CN107365387B (zh) * 2016-05-12 2022-03-15 阿思科力(苏州)生物科技有限公司 一种双特异性抗原结合构建体及其制备方法和应用
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
LT3461261T (lt) 2016-05-20 2025-08-25 Harpoon Therapeutics, Inc. Vienos grandinės kintamo fragmento cd3 surišantys baltymai
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
AU2018276419A1 (en) 2016-06-02 2019-10-17 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN106117358A (zh) * 2016-06-16 2016-11-16 中山大学 抗cd3单域抗体
CN106117361A (zh) * 2016-06-17 2016-11-16 中山大学 抗cd3单域抗体
CN106084046A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
CN106084047A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
CN106084049A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
CN106146661A (zh) * 2016-06-17 2016-11-23 中山大学 抗cd3单域抗体
CN106117360A (zh) * 2016-06-17 2016-11-16 中山大学 抗cd3单域抗体
CN106117359A (zh) * 2016-06-17 2016-11-16 中山大学 抗cd3单域抗体
CN106084048A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
CA3029209A1 (en) 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
CN106146662A (zh) * 2016-07-18 2016-11-23 中山大学 抗cd3单域抗体
UA126384C2 (uk) * 2016-09-14 2022-09-28 Тенеобіо, Інк. Антитіло, яке зв'язує cd3
AU2017331256B2 (en) 2016-09-21 2024-11-07 Aptevo Research And Development Llc CD123 binding proteins and related compositions and methods
CA3044729A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
WO2018098354A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
NZ795790A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-BCMA heavy chain-only antibodies
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN113896792B (zh) 2017-05-12 2025-08-22 哈普恩治疗公司 间皮素结合蛋白质
EP3621648A4 (en) 2017-05-12 2021-01-20 Harpoon Therapeutics, Inc. TRISPECIFIC PROTEINS MSLN AND METHOD OF USE
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
CA3065951A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
US11970540B2 (en) 2017-06-20 2024-04-30 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
TWI789399B (zh) * 2017-06-22 2023-01-11 財團法人生物技術開發中心 不對稱異二聚fc-scfv融合抗globo h及抗cd3雙特異性抗體及其於癌症治療上之用途
US11535667B2 (en) * 2017-08-28 2022-12-27 Systimmune, Inc. Anti-CD3 antibodies and methods of making and using thereof
KR102425983B1 (ko) 2017-10-13 2022-07-29 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
KR20200086278A (ko) 2017-10-18 2020-07-16 노파르티스 아게 선택적 단백질 분해를 위한 조성물 및 방법
TW201922774A (zh) 2017-11-15 2019-06-16 瑞士商諾華公司 標靶bcma嵌合抗原受體、標靶cd19嵌合抗原受體及組合療法
AU2018375738A1 (en) 2017-11-30 2020-06-11 Novartis Ag BCMA-targeting chimeric antigen receptor, and uses thereof
MX2020006494A (es) 2017-12-22 2020-11-24 Teneobio Inc Anticuerpos de cadena pesada que se unen a cd22.
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
AU2019222666B2 (en) 2018-02-15 2025-12-04 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
KR20210020903A (ko) 2018-05-14 2021-02-24 하푼 테라퓨틱스, 인크. 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
CN112533950B (zh) * 2018-06-29 2023-03-10 多玛医药科技(苏州)有限公司 抗CD3e抗体及其用途
UY38289A (es) 2018-07-02 2020-01-31 Amgen Inc Proteína de unión al antígeno anti-steap1
SG11202101825QA (en) 2018-08-31 2021-03-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
IL281413B2 (en) * 2018-09-19 2024-09-01 Fujifilm Cellular Dynamics Inc Protein l for activation and expansion of chimeric antigen receptor-modified immune cells
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
IL281683B2 (en) 2018-09-25 2023-04-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
TWI821474B (zh) * 2018-12-07 2023-11-11 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｄ３抗體及其藥物用途
CA3131036A1 (en) * 2019-02-22 2020-08-27 Wuhan Yzy Biopharma Co., Ltd. Cd3 antigen-binding fragment and application thereof
SG11202107825WA (en) 2019-02-25 2021-09-29 Novartis Ag Mesoporous silica particles compositions for viral delivery
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
KR20210149076A (ko) 2019-04-05 2021-12-08 테네오바이오, 인코포레이티드 Psma에 결합하는 중쇄 항체
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
AR120566A1 (es) 2019-11-26 2022-02-23 Novartis Ag Receptores de antígeno quiméricos y sus usos
CN113005088B (zh) * 2019-12-19 2024-06-04 苏州方德门达新药开发有限公司 工程改造的t细胞、其制备及应用
IL294461A (en) 2020-01-13 2022-09-01 Aptevo Res & Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
IL294458A (en) 2020-01-13 2022-09-01 Aptevo Res & Development Llc Formulations for protein therapeutics
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
CN115279403A (zh) 2020-02-21 2022-11-01 宏观基因有限公司 Cd137结合分子及其用途
AR121461A1 (es) 2020-02-27 2022-06-08 Novartis Ag Métodos para la fabricación de células que expresan el receptor de antígeno quimérico
KR20220147109A (ko) 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
BR112023023650A2 (pt) 2020-04-04 2024-01-30 Janux Therapeutics Inc Composições e métodos relacionados a anticorpos ativados por tumores direcionados a egfr e antígenos de células efetoras
AU2021272291A1 (en) 2020-05-11 2023-02-02 Janssen Biotech, Inc. Methods for treating multiple myeloma
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
KR20230042315A (ko) * 2020-07-20 2023-03-28 자임워크스 비씨 인코포레이티드 리간드-수용체 쌍 및 생물학적 기능성 단백질을 포함하는 융합 단백질
TW202227124A (zh) 2020-08-21 2022-07-16 瑞士商諾華公司 用於體內產生ｃａｒ表現細胞的組成物和方法
EP4225373A4 (en) * 2020-10-07 2025-01-08 Dren Bio, Inc. ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF
JP2023550148A (ja) 2020-11-20 2023-11-30 シンシア・イノベーション・インコーポレイテッド がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法
US20240384293A1 (en) 2021-04-27 2024-11-21 Novartis Ag Viral vector production system
EP4330277A4 (en) * 2021-04-28 2025-03-26 NGM Biopharmaceuticals, Inc. Multimerization of binding molecules with a variant of the constant region of an antibody
EP4330282A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
TW202244059A (zh) 2021-04-30 2022-11-16 瑞士商赫孚孟拉羅股份公司 用抗ｃｄ２０／抗ｃｄ３雙特異性抗體進行治療之給藥
WO2022240865A1 (en) * 2021-05-11 2022-11-17 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
JP2024519964A (ja) 2021-05-21 2024-05-21 アプティーボ リサーチ アンド デベロップメント エルエルシー タンパク質治療薬のための投薬レジメン
AU2022330406A1 (en) 2021-08-20 2024-03-07 Novartis Ag Methods of making chimeric antigen receptor–expressing cells
KR20240099376A (ko) 2021-11-03 2024-06-28 얀센 바이오테크 인코포레이티드 암 치료 및 bcmaxcd3 이중특이성 항체의 효능을 향상시키는 방법
EP4496631A1 (en) 2022-03-23 2025-01-29 F. Hoffmann-La Roche AG Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
TW202404637A (zh) 2022-04-13 2024-02-01 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體之醫藥組成物及使用方法
CN115029318B (zh) * 2022-05-12 2022-12-20 成都赋智健康科技有限公司 携带多特异性抗体基因的间充质干细胞及其制药用途
CN115232213B (zh) * 2022-07-19 2025-08-15 合肥天港免疫药物有限公司 双特异性抗体及其应用
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
WO2025076473A1 (en) * 2023-10-06 2025-04-10 Fred Hutchinson Cancer Center Proteins bispecific to cd3 and nkg2dl and associated uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US20030108548A1 (en) 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
ES2375561T3 (es) 1994-01-11 2012-03-02 Dyax Corporation Inhibidores de la plasmina humana derivados de dominios kunitz y �?cidos nucleicos que codifican los mismos.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
JP4219985B2 (ja) 1996-07-23 2009-02-04 タノックス ファーマ ベスローテン フェンノートシャップ 二つの共刺激経路を同時にブロックできる可溶性分子を用いたｔ細胞寛容の誘導
ES2234241T3 (es) 1998-01-23 2005-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Derivados de anticuerpo de multiples fines.
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
WO2002040545A2 (en) * 2000-11-17 2002-05-23 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
RU2179862C1 (ru) 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CN1911965B (zh) 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 结合域-免疫球蛋白融合蛋白
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20040044182A1 (en) 2001-09-17 2004-03-04 Hunt Joan S Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g
EP3321282A1 (en) 2002-09-27 2018-05-16 Xencor, Inc. Optimized fc variants and methods for their generation
RU2005141512A (ru) 2003-05-31 2007-07-20 Микромет Аг (De) Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
DE602005022830D1 (de) 2004-02-16 2010-09-23 Micromet Ag Weniger immunogene bindungsmoleküle
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
EP3770174A1 (en) 2005-10-11 2021-01-27 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
EP3056568B1 (en) * 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
NZ573132A (en) 2006-06-06 2012-05-25 Glaxo Group Ltd Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
MX380352B (es) 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
WO2008051448A2 (en) 2006-10-19 2008-05-02 Tolerx, Inc. Methods and compositions for efficient removal of protein a from binding molecule preparations
AU2007337082A1 (en) 2006-12-21 2008-07-03 Macrogenics Inc. Methods for the treatment of LADA and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
CN101990439A (zh) 2007-07-06 2011-03-23 特鲁比昂药品公司 具有置于c末端的特异性结合结构域的结合肽
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
KR20110044991A (ko) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＮＦ-α 길항제 다-표적 결합 단백질
US20110177070A1 (en) 2008-07-02 2011-07-21 Emergent Product Development Seatlle, LLC TGF-Beta Antagonist Multi-Target Binding Proteins
WO2010003101A2 (en) 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Il6 immunotherapeutics
EP2321345A1 (en) 2008-07-28 2011-05-18 Emergent Product Development Seattle, LLC Multi-specific binding proteins targeting b cell disorders
MX2011003133A (es) 2008-09-26 2011-04-21 Roche Glycart Ag Anticuerpos biespecificos anti-egfr/anti-igf-1r.
NO2344540T3 (enExample) 2008-10-02 2018-04-28
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
NZ603623A (en) 2008-10-10 2014-05-30 Emergent Product Dev Seattle Tcr complex immunotherapeutics
CN102448985B (zh) 2009-05-27 2015-08-05 霍夫曼-拉罗奇有限公司 三或四特异性抗体
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
PT2519543T (pt) * 2009-12-29 2016-10-07 Emergent Product Dev Seattle Proteínas de ligação de heterodímero e suas utilizações
EP2699596A4 (en) 2011-04-22 2015-01-14 Emergent Product Dev Seattle PROSTATE-SPECIFIC MEMBRANE-BINDING PROTEINS AND COMPOSITIONS AND METHOD THEREFOR
KR101308922B1 (ko) * 2012-02-15 2013-09-23 주식회사 경동나비엔 연소기기용 듀얼 벤츄리
CA2870545A1 (en) 2012-04-20 2013-10-24 Emergent Product Development Seattle, Llc Cd3 binding polypeptides

Also Published As

Publication number Publication date
EP2839019A2 (en) 2015-02-25
MX366813B (es) 2019-07-25
HK1208707A1 (en) 2016-03-11
HK1207398A1 (en) 2016-01-29
SG11201406346SA (en) 2014-11-27
KR20150004856A (ko) 2015-01-13
BR112014025830A8 (pt) 2017-10-10
AU2017228643B2 (en) 2019-12-05
JP2015521032A (ja) 2015-07-27
WO2013158856A2 (en) 2013-10-24
CA2870545A1 (en) 2013-10-24
AU2013249267A1 (en) 2014-10-23
UA119227C2 (uk) 2019-05-27
US10202452B2 (en) 2019-02-12
IL235093B (en) 2019-09-26
CN104487587A (zh) 2015-04-01
SG10201608307WA (en) 2016-11-29
EP2839019A4 (en) 2016-03-30
RU2014142166A (ru) 2016-06-10
IL235093A0 (en) 2014-12-31
AU2017228643A1 (en) 2017-10-05
IN2014MN02293A (enExample) 2015-08-07
MX2014012578A (es) 2015-05-11
RU2673153C2 (ru) 2018-11-22
JP2018138039A (ja) 2018-09-06
JP6509724B2 (ja) 2019-05-08
US20150232557A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
BR112014025830A2 (enExample)
BR112014017635A2 (enExample)
BR112014017614A2 (enExample)
BR112014018331A2 (enExample)
BR112014017625A2 (enExample)
BR112014017659A2 (enExample)
BR112014017592A2 (enExample)
BR112014019838A2 (enExample)
BR112014017646A2 (enExample)
BR112014018155A2 (enExample)
BR112014017607A2 (enExample)
BR112014017638A2 (enExample)
BR112014024753A2 (enExample)
BR112014019146A2 (enExample)
BR112014017609A2 (enExample)
BR112014017634A2 (enExample)
BR112014017644A2 (enExample)
BR112014017588A2 (enExample)
BR112014017618A2 (enExample)
BR112014017647A2 (enExample)
BR112014017623A2 (enExample)
BR112014017652A2 (enExample)
BR112014017630A2 (enExample)
BR112014017627A2 (enExample)
BR112014017621A2 (enExample)

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: APTEVO RESEARCH AND DEVELOPMENT LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: COM BASE NA RESOLUCAO 81/2013, SOLICITA-SE QUE SEJA APRESENTADO, EM ATE 60 (SESSENTA) DIAS, DECLARACAO DE LISTAGEM DE SEQUENCIA ASSINADA, NOS MOLDES DA RESOLUCAO NO 187 DE 27/04/2017, REFERENTE AO CONTEUDO APRESENTADO NA PETICAO NO 020140034220 DE 17/11/2014.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements